Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients Without Diabetes With Acute Myocardial Infarction at Increased Risk for Subsequent Development of Heart Failure

NCT04564742 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04564742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04564742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients Without Diabetes With Acute Myocardial Infarction at Increased Risk for Subsequent Development of Heart Failure
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
December 22, 2020
Completion date
July 5, 2023
Enrollment
4,017 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction, heart failure